Skip to main content
Erschienen in: Journal of Cancer Education 1/2016

01.03.2016

Follow-up Care Education and Information: Identifying Cancer Survivors in Need of More Guidance

verfasst von: Denalee M. O’Malley, Shawna V. Hudson, Pamela A. Ohman-Strickland, Alicja Bator, Heather S. Lee, Daniel A. Gundersen, Suzanne M. Miller

Erschienen in: Journal of Cancer Education | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Cancer survivors engage in cancer screenings and protective health behaviors at suboptimal rates despite their increased risk for future illness. Survivorship care plans and other educational strategies to prepare cancer survivors to adopt engaged roles in managing long-term follow-up care and health risks are needed. In a sample of cancer survivors, we identified patient characteristics and psychosocial predictors associated with increased follow-up care informational needs. Cross-sectional surveys were administered to early-stage breast and prostate survivors (N = 278; 68 % breast) at least 2 years post treatment from four community hospital programs in New Jersey between May 2012 and July 2013. Patient demographics, medical history, psychosocial characteristics (i.e., worries about the future, fear of disease recurrence, and patient activation), and perceptions of oncology and primary care were assessed. African-American survivors (AOR = 2.69, 95 % confidence interval [CI] 1.27–5.68) and survivors with higher comorbidity (AOR = 1.16, CI 1.01-1.33) were more likely to want additional information to guide follow-up care. Adjusting for race and comorbidities, survivors who wanted more information to guide their follow-up care reported greater worries about the future (p < 0.05) and fears about disease recurrence (p < 0.05) compared to those who did not want additional information. Results emphasize the need to develop cancer survivorship educational strategies that are both responsive to the needs of specific populations (e.g., African-American survivors and patients with multiple comorbidities) and the psychosocial profiles that motivate requests for more extensive follow-up guidance.
Literatur
1.
Zurück zum Zitat DeSantis CE, Lin CC, Mariotto AB, et al (2014) Cancer treatment and survivorship statistics, 2014. CA: A Cancer J Clin DeSantis CE, Lin CC, Mariotto AB, et al (2014) Cancer treatment and survivorship statistics, 2014. CA: A Cancer J Clin
2.
Zurück zum Zitat de Moor JS, Mariotto AB, Parry C, et al (2013) Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev 22(4):561–570PubMedCentralCrossRefPubMed de Moor JS, Mariotto AB, Parry C, et al (2013) Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev 22(4):561–570PubMedCentralCrossRefPubMed
3.
Zurück zum Zitat Underwood JM, Townsend JS, Stewart SL, et al (2012) Surveillance of demographic characteristics and health behaviors among adult cancer survivors—behavioral risk factor surveillance system, United States, 2009. MMWR Surveill Summ 61(Suppl 1):1–23PubMed Underwood JM, Townsend JS, Stewart SL, et al (2012) Surveillance of demographic characteristics and health behaviors among adult cancer survivors—behavioral risk factor surveillance system, United States, 2009. MMWR Surveill Summ 61(Suppl 1):1–23PubMed
4.
Zurück zum Zitat Earle CC, Neville BA (2004) Under use of necessary care among cancer survivors. Cancer 101(8):1712–1719CrossRefPubMed Earle CC, Neville BA (2004) Under use of necessary care among cancer survivors. Cancer 101(8):1712–1719CrossRefPubMed
6.
Zurück zum Zitat Hewitt ME, Greenfield S, Stovall E, et al (2006) From cancer patient to cancer survivor: lost in transition. National Academies Press. xxv, Washington, D.C., p xxv, 506 p Hewitt ME, Greenfield S, Stovall E, et al (2006) From cancer patient to cancer survivor: lost in transition. National Academies Press. xxv, Washington, D.C., p xxv, 506 p
7.
Zurück zum Zitat Earle CC, Ganz PA (2012) Cancer survivorship care: don’t let the perfect be the enemy of the good. J Clin Oncol 30(30):3764–3768CrossRefPubMed Earle CC, Ganz PA (2012) Cancer survivorship care: don’t let the perfect be the enemy of the good. J Clin Oncol 30(30):3764–3768CrossRefPubMed
8.
Zurück zum Zitat Oeffinger KC, McCabe MS (2006) Models for delivering survivorship care. J Clin Oncol 24(32):5117–5124CrossRefPubMed Oeffinger KC, McCabe MS (2006) Models for delivering survivorship care. J Clin Oncol 24(32):5117–5124CrossRefPubMed
9.
Zurück zum Zitat Hudson SV, Miller SM, Hemler J, et al (2012) Adult cancer survivors discuss follow-up in primary care: ‘not what I want, but maybe what I need’. Ann Fam Med 10(5):418–427PubMedCentralCrossRefPubMed Hudson SV, Miller SM, Hemler J, et al (2012) Adult cancer survivors discuss follow-up in primary care: ‘not what I want, but maybe what I need’. Ann Fam Med 10(5):418–427PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Parry C, Kent EE, Forsythe LP, et al (2013) Can’t see the forest for the care plan: a call to revisit the context of care planning. J Clin Oncol 31(21):2651–2653PubMedCentralCrossRefPubMed Parry C, Kent EE, Forsythe LP, et al (2013) Can’t see the forest for the care plan: a call to revisit the context of care planning. J Clin Oncol 31(21):2651–2653PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Burg MA, Lopez ED, Dailey A, et al (2009) The potential of survivorship care plans in primary care follow-up of minority breast cancer patients. J Gen Intern Med 24(2):467–471PubMedCentralCrossRef Burg MA, Lopez ED, Dailey A, et al (2009) The potential of survivorship care plans in primary care follow-up of minority breast cancer patients. J Gen Intern Med 24(2):467–471PubMedCentralCrossRef
12.
Zurück zum Zitat Hewitt ME, Bamundo A, Day R, et al (2007) Perspectives on post-treatment cancer care: qualitative research with survivors, nurses, and physicians. J Clin Oncol 25(16):2270–2273 Hewitt ME, Bamundo A, Day R, et al (2007) Perspectives on post-treatment cancer care: qualitative research with survivors, nurses, and physicians. J Clin Oncol 25(16):2270–2273
13.
Zurück zum Zitat Miller SM (1995) Monitoring versus blunting styles of coping with cancer influence the information patients want and need about their disease. Implications for cancer screening and management. Cancer 76(2):167–177CrossRefPubMed Miller SM (1995) Monitoring versus blunting styles of coping with cancer influence the information patients want and need about their disease. Implications for cancer screening and management. Cancer 76(2):167–177CrossRefPubMed
14.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRefPubMed Charlson ME, Pompei P, Ales KL, et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRefPubMed
15.
Zurück zum Zitat Hibbard JH, Mahoney ER, Stockard J, et al (2005) Development and testing of a short form of the patient activation measure. Health Serv Res 40(6p1):1918–1930PubMedCentralCrossRefPubMed Hibbard JH, Mahoney ER, Stockard J, et al (2005) Development and testing of a short form of the patient activation measure. Health Serv Res 40(6p1):1918–1930PubMedCentralCrossRefPubMed
16.
Zurück zum Zitat Flocke SA, Miller WL, Crabtree BF (2002) Relationships between physician practice style, patient satisfaction, and attributes of primary care. J Fam Pract 51(10):835–840PubMed Flocke SA, Miller WL, Crabtree BF (2002) Relationships between physician practice style, patient satisfaction, and attributes of primary care. J Fam Pract 51(10):835–840PubMed
17.
Zurück zum Zitat Ashing-Giwa K, Tapp C, Brown S, et al (2013) Are survivorship care plans responsive to African-American breast cancer survivors?: voices of survivors and advocates. J Cancer Surviv 7(3):283–291CrossRefPubMed Ashing-Giwa K, Tapp C, Brown S, et al (2013) Are survivorship care plans responsive to African-American breast cancer survivors?: voices of survivors and advocates. J Cancer Surviv 7(3):283–291CrossRefPubMed
18.
Zurück zum Zitat Kantipur M et al (2009) Transitioning to breast cancer survivorship: perspectives of patients, cancer specialists, and primary care providers. J Gen Intern Med 24(2):459–466 Kantipur M et al (2009) Transitioning to breast cancer survivorship: perspectives of patients, cancer specialists, and primary care providers. J Gen Intern Med 24(2):459–466
19.
Zurück zum Zitat Campbell LC, Keefe FJ, Scipio C, et al (2007) Facilitating research participation and improving quality of life for African American prostate cancer survivors and their intimate partners. Cancer 109(S2):414–424CrossRefPubMed Campbell LC, Keefe FJ, Scipio C, et al (2007) Facilitating research participation and improving quality of life for African American prostate cancer survivors and their intimate partners. Cancer 109(S2):414–424CrossRefPubMed
20.
Zurück zum Zitat Beckjord EB, Arora NK, McLaughlin W, et al (2008) Health-related information needs in a large and diverse sample of adult cancer survivors: implications for cancer care. J Cancer Surviv 2(3):179–189CrossRefPubMed Beckjord EB, Arora NK, McLaughlin W, et al (2008) Health-related information needs in a large and diverse sample of adult cancer survivors: implications for cancer care. J Cancer Surviv 2(3):179–189CrossRefPubMed
21.
Zurück zum Zitat Konety BR, Cowan JE, Carroll PR (2008) Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE< sup>®</sup> J Urol 179(5):1797–1803CrossRefPubMed Konety BR, Cowan JE, Carroll PR (2008) Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE< sup>®</sup> J Urol 179(5):1797–1803CrossRefPubMed
22.
Zurück zum Zitat Yancik R, Wesley MN, Ries LA, et al (2001) Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285(7):885–892CrossRefPubMed Yancik R, Wesley MN, Ries LA, et al (2001) Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285(7):885–892CrossRefPubMed
23.
Zurück zum Zitat Pal SK, Hurria A (2010) Impact of age, sex, and comorbidity on cancer therapy and disease progression. J Clin Oncol 28(26):4086–4093CrossRefPubMed Pal SK, Hurria A (2010) Impact of age, sex, and comorbidity on cancer therapy and disease progression. J Clin Oncol 28(26):4086–4093CrossRefPubMed
Metadaten
Titel
Follow-up Care Education and Information: Identifying Cancer Survivors in Need of More Guidance
verfasst von
Denalee M. O’Malley
Shawna V. Hudson
Pamela A. Ohman-Strickland
Alicja Bator
Heather S. Lee
Daniel A. Gundersen
Suzanne M. Miller
Publikationsdatum
01.03.2016
Verlag
Springer US
Erschienen in
Journal of Cancer Education / Ausgabe 1/2016
Print ISSN: 0885-8195
Elektronische ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-014-0775-y

Weitere Artikel der Ausgabe 1/2016

Journal of Cancer Education 1/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.